Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA removes clinical hold on RespireRx’s CX1739 ampakine drug
RespireRx plans to start a phase 2A clinical trial by the end of this month to confirm the ability of CX1739 to antagonize the respiratory depressant effects of
RespireRx plans to start a phase 2A clinical trial by the end of this month to confirm the ability of CX1739 to antagonize the respiratory depressant effects of
The trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma failed to hit its primary target. AstraZeneca senior vice president, head of
NS2 is an aldehyde-binding small molecule based on a platform technology that centers on trapping aldehydes, which are toxic and pro-inflammatory mediators of several diseases. It lowers aldehyde
The novel single-dose antibiotic Brilacidin is indicated to treat ABSSSI caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A SPA is a written agreement between the FDA and
The approval of new 60mg dose is indicated to treat patients who have suffered a heart attack at least one year prior and are at high risk of
The tumors should be progressive, well-differentiated and non-functional. The data supporting the new indication was generated was based on a 302-patient trial comparing everolimus with placebo, both in
Precision BioSciences’ ARCUS genome editing technology will be used to develop an allogeneic chimeric antigen receptor (CAR T) cell therapeutic pipeline directed towards areas of major unmet need
Last December, AstraZeneca agreed to acquire a 55% stake in privately-owned biotech firm Acerta Pharma for $4bn. Acalabrutinib has been recommended as an orphan product for chronic lymphocytic
California-based Vantage Oncology offers radiation oncology, medical oncology and other cancer care services. It will add over 50 cancer centers across 13 US states to McKesson’s business. Biologics
The latest round of funding brings Rani Therapeutics’ total investment to over $70m. Other investors in the round were Virtus Inspire Ventures and Ping An Ventures. The company’s